Finally, in the established CARS phase (beyond 7 d), the focus should shift to immune restoration using agents such as GM-CSF or PD-1 inhibitors, to strictly avoid cytokine antagonists and emphasize infection surveillance to prevent inflammatory rebound. This evidence concerns the gene PDCD1 and infection.